

**2026 Colorado Protein Stability Conference
August 3 – August 6
Beaver Run Resort
Breckenridge, Colorado**

**Presented by the University of Colorado
Center for Pharmaceutical Biotechnology**

Conference Schedule

Monday, August 3

- 3:00 pm Registration Opens
- 7:00 pm Opening Reception
 Copper Top II/III

Tuesday, August 4

- 7:00 am Breakfast
 Copper Top II/III
 Sponsored by Genentech
- 8:00 am Welcoming Comments
 Colorado Ballroom
- Protein Stability and Dynamics - I
Colorado Ballroom
- 8:05 am Tobin Sosnick
 University of Chicago
 Should we be surprised that biothermodynamics works so well?
- 8:40 am Lauren Porter
 NIH
 Fold switching and protein stability
- 9:15 am Vladimir Uversky

University of South Florida
*Lost in transitions: Pathological cost of
multifunctionality*

9:50 am Coffee Break

Protein Stability and Dynamics - II
Colorado Ballroom

10:20 am Nikolay Dokholyan
University of Virginia
Early Molecular Events in Neurodegeneration

10:55 am Kayla Sprenger
University of Colorado
*Decoding how protein-protein interactions, stability, and
conformational dynamics drive pathogenic mechanisms
across neurodegenerative and infectious diseases via MD
simulations*

11:30 am Daumantas Matulis
Vilnius University
*Stabilization of proteins by small molecule ligands - use
for characterization and affinity determination*

12:05 pm Introduction to Tuesday Lunch Sponsor KBI Biopharma

12:15 pm Introduction to Wednesday Lunch Sponsor Gator Bio

12:25 pm Lunch
Copper Top II/III
Sponsored by KBI Biopharma

Vaccines, Solid state protein stability, and AAVs
Colorado Ballroom

2:00 pm Neil King
University of Washington
*Machine learning-enabled antigen and nanoparticle
vaccine design*

- 2:35 pm Eric Munson
Purdue University
Advanced Characterization Methods for Assessing Stability of Protein Formulations in the Solid State
- 3:10 pm Susumu Uchiyama
Osaka University
rAAV as a Heterogeneous Particle Ensemble: Current Understanding of Its Quality Attributes and Relation to Efficacy and Safety
- 3:45 pm Coffee Break
- Antibody Optimization and Developability
- 4:15 pm Pete Tessier
University of Michigan
Multi-property antibody optimization using machine learning
- 4:50 pm Hristo Svilenov
Technische Universität München
Looking at unconventional antibodies from a developability perspective
- 5:25 pm Tim Menzen
Coriolis
To platform or not to platform: strategic considerations for antibody formulation in early clinical development
- 6:00 pm Introduction to Reception Sponsor Pfanstiehl
- 6:10 pm Colorado Beer Tasting Reception
Copper Top II/III
Sponsored by Pfanstiehl

Wednesday, August 5

- 7:30 am Breakfast

Copper Top II/III
Sponsored by Alexion

8:30 am Poster Setup
Colorado Ballroom

9:00 am Poster Session
Colorado Ballroom

9:00 am – 11:00 am Even-numbered posters presented

11:00 am – 1:00 pm Odd-numbered posters presented

1:00 pm Lunch
Copper Top II/III
Sponsored by Gator Bio

2:00 pm Afternoon free time and dinner on your own

Thursday, August 6

7:00 am Breakfast
Copper Top II/III
Sponsored by Gilead

8:00 am Welcoming Comments
Colorado Ballroom

ADCs and excipients
Colorado Ballroom

8:05 am Shouvik Roy
Merck
*New challenges in ADC Drug Product Development -
awareness and mitigation*

8:40 am Lea Sorret
Ten23 Health
*Integrated Strategies for ADC Development: Ensuring
Stability, Scalability, and Safe Administration of ADCs*

9:15 am Patrick Garidel
Boehringer Ingelheim
A decade of polysorbate degradation research: current status

9:50 am Coffee Break

Excipients in Protein Formulations
Colorado Ballroom

10:20 am Satish Singh
Astria Therapeutics
How Sweet it is: Revisiting Sucrose and Trehalose as Stabilizers in Protein Formulations

10:55 am Christian Schoeneich
University of Kansas
Near UV and visible light degradation of therapeutic proteins: the role of common excipients

11:30 am Ashutosh Rao
FDA
Scientific and Regulatory perspectives on excipients used in protein formulations

12:05 pm Lunch
Copper Top II/III

Protein stability, aggregation, and immunogenicity
Colorado Ballroom

2:00 pm Benjamin Walters
Genentech
Bridging Stability and Biophysical Outcomes in Therapeutic Proteins

2:35 pm Joseph Cohen
Amgen

A high threshold of aggregate numbers is needed to induce immunogenic response in vitro, in vivo and in the clinic

- 3:10 pm Daniela Verthelyi
FDA
Immunogenicity risk assessments: The impact of aggregates and innate immune response modulating impurities
- 3:45 pm Coffee Break
- Safe and Stable Formulations
- 4:15 pm Parag Kolhe
Pfizer
Formulation and Process Considerations for developing patient centric drug product dosage forms
- 4:50 pm Erica Schlesinger
Seran Bio
Formulation without Compromise: Dose, Convenience, Stability
- 5:25 pm Christina Vessely
Biopharma Pathways
Protein Drug Stability Assessments: ICH Q1 and Beyond
- 6:00 pm Student Poster Awards & Closing Comments
Colorado Ballroom
- 6:10 pm Closing Reception
Copper Top II/III